1. Introduction {#sec1}
===============

Tobacco use has steadily declined over the last four decades \[[@B1]\]. In parallel, there has been a decline in cancers of most sites in the upper aerodigestive tract \[[@B2]\]. The exception to this trend is cancers of the oropharynx, particularly those of the palatine and lingual tonsils, which are caused by oncogenic subtypes of the human papillomavirus (HPV) \[[@B3]\]. The rise in incidence of HPV-positive head and neck squamous cell carcinoma (HNSCC) has been dramatic, causing the rates of tonsillar cancer to increase by as much as threefold in some countries \[[@B3], [@B4]\]. HPV-positive patients experience markedly better survival, and their tumors are molecularly distinct from traditional head and neck cancers \[[@B5]\]. Overexpression of p16 and proteolysis of p53 are nearly universal in HPV-positive tumors, in contrast to frequent loss of p16 and point mutations in p53 that are found in HPV-negative cancers \[[@B5]\]. However, the specific mechanisms responsible for improved survival in HPV-positive patients have not been fully elucidated.

Next-generation sequencing has yielded important insights into the pathogenesis of other cancers by identifying biomarkers and therapeutic targets. High-throughput sequencing of HNSCC tumors has recently been reported, and NOTCH inactivation was the most significant finding \[[@B6], [@B7]\]. This pilot study aims to contrast the mutations seen in an HPV-positive and an HPV-negative tumor using whole exome sequencing and further our understanding about the mutations that define HNSCC.

2. Methods {#sec2}
==========

2.1. Patient Selection and Tumor and Blood Sample Collection {#sec2.1}
------------------------------------------------------------

Ethics approval was obtained from Western University Health Sciences Research Ethics Board. Informed consent was obtained from patients undergoing ablative surgery for head and neck cancer to have a portion of their tumor stored, a 10 mL blood sample taken, and their clinical parameters prospectively collected. Two patients were identified for this pilot study: a 49-year-old nonsmoking male with a T2N0 tonsillar cancer treated with transoral robotic surgery and neck dissection and an 81-year-old female with a history of heavy smoking with a T2N0 oral tongue cancer treated with partial glossectomy, neck dissection, and free flap reconstruction. Primary site tumor specimens were taken from the center of the resection specimen. Ten mL of venous blood were drawn intraoperatively into heparinized collection tubes.

2.2. p16 Immunohistochemistry {#sec2.2}
-----------------------------

For each patient, a portion of the primary tumor was fixed in formalin and embedded in paraffin. The blocks were then sectioned (5 *μ*m thick). p16 immunohistochemistry was performed as previously described using a mouse monoclonal antibody against p16 (MTM Laboratories, Heidelberg, Germany) at 1 : 500 dilution \[[@B8]\]. Immunohistochemistry scoring was conducted by two study pathologists (BW and KK) blinded to HPV status and patient information. Scoring was as described by Begum et al. with strong and diffuse staining (\>80 percent of tumor cells) regarded as a positive result, and negative if absent or focal \[[@B9]\].

2.3. DNA Extraction from Blood and Tumor Tissue {#sec2.3}
-----------------------------------------------

DNA was extracted from 10 mL of whole blood using the QIAmp Blood Maxi kit following instructions provided by the manufacturer (Qiagen, Valencia, CA, USA). DNA was extracted from approximately 25 mg of primary tumor using the AllPrep DNA/RNA/Protein kit (Qiagen).

2.4. *In Situ* Hybridization for Human Papillomavirus Testing {#sec2.4}
-------------------------------------------------------------

Slides were deparaffinized by immersion in xylene, rehydrated in alcohol, and rinsed in water. Slides were then treated with 20 *μ*g/mL proteinase K (Sigma, St. Louis, MO) for 30 minutes, followed by immersion in 0.3% H~2~O~2~ in methanol at room temperature for 20 minutes. Slides were then treated for 10 minutes with avidin solution followed by biotin solution. The DakoGenpoint (Dako, Carpinteria, CA, USA) biotinylated probe that identifies high-risk subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 was added to the slides. The slides were then covered and heated to 92°C for 5 minutes and then incubated at 37°C for 18 hours. DNA-DNA hybrids were detected by successive incubation with 1 : 100 diluted primary horseradish peroxidase-conjugated streptavidin (streptavidin-HRP) for 15 min, with biotinyltyramide for 15 min, and with secondary streptavidin-HRP for 15 min. A cervical cancer was used as a positive control, and a tonsil specimen from a healthy child undergoing tonsillectomy for sleep apnea was used as a negative control. Punctuate hybridization signals localized to the tumor cell nuclei defined an HPV-positive tumor. Scoring was conducted by the two study pathologists (BW and KK).

2.5. PCR Confirmation of Patient HPV Status {#sec2.5}
-------------------------------------------

Patient DNA was extracted from thin section tissue slices. Briefly, a single pathology slide from each patient was deparaffinized, and then the tumor tissue was scraped into a 1.5 mL eppendorf tube containing 50 *μ*L of Arcturus PicoPure extraction buffer, containing proteinase K (Applied Biosystems). The sample was digested at 65°C for 16 hours. The proteinase K was inactivated at 95°C for 10 minutes, and DNA was used directly in PCR. Primers were designed against unique regions of the E6-E7 loci of HPV type 16 and type 18 and synthesized by Sigma Genosys (Oakville, Canada, [Table 1](#tab1){ref-type="table"}). Primers were also synthesized against GAPDH, a cellular gene used as a positive control for the PCR reactions. 0.2 *μ*L of DNA extracted from the tumor tissue was added to the appropriate reaction tubes. PCR products were amplified with DNA Phusion polymerase (Thermo Scientific, Nepean, Canada) in 20 *μ*L reactions following the manufacturer\'s instructions.

2.6. Exome Sequencing {#sec2.6}
---------------------

Exome libraries were created at The Centre for Advanced Genomics (Toronto, Canada) according to the manufacturer\'s standard protocol for SOLiD library preparation (Applied Biosystems, Carlsbad, CA, USA). Three *μ*g of genomic DNA extracted from matched patient blood and tumor samples was sheared via sonication using the Covaris (S-Series) instrument. The ends of fragmented DNA were repaired and ligated to SOLiD P1 and A1 adapters provided in the Agilent Human All Exon 50 Mb Kit following the manufacturers protocol (Agilent, Santa Clara, CA, USA). The exomes were then captured using the Agilent Human All Exon 50 Mb kit, and the amplified library was purified with AMPure XP beads (Beckman Coulter Genomics, Danvers, MA). Sequencing was performed with the SOLiDToP Paired End Sequencing Kit (Applied Biosystems). The image data collected was analyzed using the ABI corona pipeline to generate DNA reads that were mapped to the reference human genome (UCSC\'s hg19) using BFAST \[[@B10]\].

2.7. Bioinformatics {#sec2.7}
-------------------

Samples were processed as matched sets through the Genome Analysis ToolKit (GATK) v1.3-16 pipeline \[[@B11]\]. Samples were initially locally realigned using the IndelRealigner walker from the GATK package with known insertions and deletions found in dbSNP 135. This was followed by base quality recalibration from GATK. Default parameters were used for both steps except for SOLiD specific parameters in the recalibration step. Reads without any color space calls were marked as failing vendor quality and thus were removed from further downstream analysis. In addition, reads that had a reference base inserted into the reads due to inconsistent color space calls had those bases set to Ns with base qualities of zero. Finally variants were called and filtered using the GATK UnifiedGenotyper and VariantFiltration walkers again with default settings.

To be considered for further downstream analysis, a tumor variant had to have at least 8x coverage within the target regions 37,038,261 sites (71.86%) for the HPV-positive tumor and 39,150,091 sites (75.96%) for the HPV-negative tumor that met this criterion. In addition to coverage, the following requirements had to be identified by the VariantFiltration walker:variant quality equal to or greater than 30,variant confidence/quality by depth (QD) equal to or greater than 2.0,MQ0 \< 4 and MQ0/(1.0 ∗ DP)) \< 0.1, where MQ0 is the total mapping quality zero reads and DP is the unfiltered read depth.

A reference variant required a minimum read depth of 8x within the target region for further consideration (38,673,520 sites (75.03%) and 38,058,450 sites (73.84%) for HPV-positive and HPV-negative tumors, resp.). This presented 36,020,799 and 37,049,778 comparable sites in the HPV-positive and HPV-negative tumors. Using in-house custom Perl code, somatic variants within the targeted regions were identified. To be classified as a somatic variant the following conditions had to be met: (1) a tumor variant was identified by GATK that met the above filtration requirements and (2) the corresponding position in the normal sample had 8x coverage and did not have a GATK variant call. Somatic variants were annotated with refGene annotations (<http://varianttools.sourceforge.net/Annotation/RefGene>), and consequences were identified using ANNOVAR v2012-03-08 \[[@B12]\].

3. Results {#sec3}
==========

3.1. p16 Immunohistochemistry and HPV Testing {#sec3.1}
---------------------------------------------

Genomic DNA was extracted from matching tumor and blood samples from two head and neck cancer patients: patient 1 was a 49-year-old nonsmoking and nondrinking male, and patient 2 was an 81-year-old female smoker. Patient demographics, treatment details, and histopathologic parameters are outlined in [Table 2](#tab2){ref-type="table"}. Tumor sections from each patient were stained with hematoxylin and eosin (Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}). Patient 1 stained diffusely positive for p16 ([Figure 1(c)](#fig1){ref-type="fig"}), while the tumor tissue from patient 2 was negative for p16 ([Figure 1(d)](#fig1){ref-type="fig"}). *In situ* hybridization testing with the broad-spectrum HPV probe demonstrated strong punctate staining within nuclei of the tumor of patient 1, consistent with high-risk HPV infection ([Figure 1(e)](#fig1){ref-type="fig"}). HPV-specific, punctate nuclear staining was absent in the tumor of patient 2 ([Figure 1(f)](#fig1){ref-type="fig"}).

We employed primers designed specifically against unique portions of the E6-E7 region of HPV type 16 and type 18 to confirm the HPV status of the patients in this study. The GAPDH control was amplified from both patients; as expected, only patient 1 was HPV type 16 positive ([Figure 2](#fig2){ref-type="fig"}). Patient 2 was negative for HPV type 16, and both patients were HPV type 18 negative (data not shown).

3.2. Exome Capture and Raw Sequencing Results {#sec3.2}
---------------------------------------------

The exomes from tumor tissue and matched blood samples from each patient were sequenced. For each tumor or blood sample, approximately 1.2 billion bases were sequenced, 86% of which were specific for exome sequences. The mean coverage of the exome targets was 28.1-fold, with 91.6% of the targets being sequenced at least once and 67.4% sequenced at least ten times. The exome capture and sequencing results were within the normal range of performance specified by the manufacturer and are comparable with published results \[[@B13]\].

3.3. Bioinformatic Interpretation of Sequencing Results {#sec3.3}
-------------------------------------------------------

We compared the sequencing results of each patient\'s tumor to their matched blood samples in order to eliminate background germline variations and to focus on somatic alterations unique to the tumor genome. Although the exome capture is designed to target coding regions, some intergenic and intron regions adjacent exons are captured in the process. A complete listing of the identified variants in coding and noncoding regions for the HPV-positive and HPV-negative tumors is reported in Tables S1 and S2, respectively (see Supplementary Material available online at doi: 10.5402/2012/809370). Only the variants that occurred within exons are listed in Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}. Fifty-eight somatic mutations were noted in the HPV-positive tumor, 32 of which were nonsynonymous mutations within exons. Seventy-three mutations were observed in the HPV-negative tumor, including 36 coding mutations. Forty-nine of the mutated genes identified in this study were also shown to harbor mutations in large-scale sequencing studies (Tables S1 and S2) \[[@B6], [@B7]\].

No mutations were noted in TP53, CDKN2A (p16), or the NOTCH receptors in either tumor. However, multiple mutations were noted in zinc finger genes (ZNF3, 10, 229, 470, 543, 616, 664, 638, 716, and 799) and mucin genes (MUC4, 6, 12, and 16). Mutations were noted in MUC12 in both tumors.

Patient characteristics, PCR analysis, *in situ* hybridization testing, and immunohistochemistry all indicated that patient 1 was HPV type 16 positive (HPV type 18 negative by PCR) and that patient 2 was HPV negative (both type 16 and type 18 negative). When we used our four compiled exome sequences (blood and tumor from both patients) as queries against the HPV type 16 genomic sequence (RefSeq NC_001526.2), the tumor sequence from patient 1 matched numerous regions (39 hits) of the HPV 16 genome ([Figure 3](#fig3){ref-type="fig"}). Matches were identified to all the HPV type 16 genes (except E4) suggesting that the HPV type 16 genome had integrated into the tumor genome of patient 1. The tumor sample from patient 2 and the blood samples from both patients did not align to any specific HPV sequences.

4. Discussion {#sec4}
=============

HPV-positive head and neck squamous cell carcinoma (HNSCC) has been described as molecularly distinct from traditional head and neck cancer \[[@B5]\]. The human papillomavirus (HPV) oncoproteins E6 and E7 promote carcinogenesis by degrading the tumor suppressors p53 and retinoblastoma protein (Rb), respectively. In contrast, p53 is not degraded in HPV-negative HNSCC but is frequently mutated, and p16 is often lost through homozygous deletion, methylation, or, less frequently, point mutation \[[@B5], [@B14]\]. This might lead one to believe that carcinogens like tobacco and alcohol would promote HNSCC comprised of a large number of mutations in many different pathways. In contrast HPV-positive cancers, modulated by the activities of viral oncoproteins, might not accumulate a large number of cellular mutations. In our study, we provided quadruple confirmation of tumor HPV status with p16 immunohistochemistry, HPV *in situ* hybridization, HPV detection by PCR, and detection of the HPV 16 genome sequences within patient 1\'s sequenced exome. We observed more mutations in the HPV-negative tumor when compared to the HPV-positive tumor, although the absolute difference was not dramatic (73 versus 58, resp.). Two large-scale exome sequencing efforts characterizing HNSCC have been reported recently \[[@B6], [@B7]\]. The study led by Stransky et al. reported twice as many mutations in the HPV-negative samples (4.83 mutations/Mb versus 2.28 mutations/Mb) \[[@B7]\]. The second group examined a set of 32 patients, four of which were HPV positive and reported on a subset of mutations that were identified by exome sequencing and confirmed by PCR. In this subset of genes, there were four times as many mutations in the HPV-negative tumors (20.6 ± 16.7 versus 4.8 ± 3 mutations in the HPV-positive tumors) \[[@B6]\]. Given the broad range of mutations seen in the HPV-negative cancers, our finding of slightly more mutations in the HPV-negative tumor is consistent with their results. As expected we did not identify TP53 or p16 mutations in the HPV-positive tumor; however these two genes appeared as wild type in the HPV-negative tumor as well. The lack of a p16 mutation in the setting of low expression levels as evidenced by immunohistochemistry may reflect that it has been inactivated by promoter methylation, the second most common cause of p16 loss \[[@B14]\].

Only a single genetic mutation (Muc12) was shared by both HPV-positive and HPV-negative tumor samples. The cell surface associated Muc12 was the only mucin identified in the HPV-negative tumor. In contrast, the HPV-positive tumor had five mutations in four different mucin genes, including the secreted Muc6, and the transmembrane bound Muc4, Muc12 and Muc16. Stransky et al. reported mutations in all the above mucins except for Muc12 \[[@B7]\]. Mucins are known to be involved in the development of epithelial cancer where they are often overexpressed, disrupting the epithelial cell polarity and promoting the epithelial to mesenchymal transition (EMT) phenotype \[[@B15]\]. Multiple damaging mutations within the mucins of HPV-positive tumor may suggest another cellular difference between these two distinct tumor types.

We also found multiple mutations in the zinc finger (ZNF) family genes in both tumor types. The ZNF family represents a large group of molecules which are involved in various aspects of transcriptional regulation \[[@B16]\]. There were almost twice as many ZNF mutated genes in the HPV-positive sample. Although there were a total of 11 ZNF mutations between the two tumor types, there were no shared ZNF members mutated in both cancers. Stransky et al. reported 50% of the same ZNF mutations that we found in both tumor samples suggesting that genetic changes to this family of transcription regulators may be important in the development of HNSCC \[[@B7]\]. Not enough is known about the role of mucins and ZNF proteins in HNSCC. These molecules may warrant further study.

We confirmed that the sequence from the human pathogen HPV type 16 was identified within exome sequence of a HNSCC tumor. In order for HPV to be oncogenic, the viral E2 protein, which represses the expression of E6 and E7, must be lost \[[@B17]\]. This only occurs during integration when the episomal HPV DNA breaks within the E2 gene. PCR detection of E6 and E7 can detect both episomal and integrated forms and thus cannot distinguish between a superficial HPV infection and integrated viral DNA causing the cancer \[[@B17]\]. An additional benefit of whole exome sequencing is the detection of integrated HPV DNA. In Stransky\'s study, exome sequencing appeared even more sensitive than PCR for detection of HPV, as it identified the presence of HPV 16 in 14 of 73 cases versus 11 for PCR \[[@B7]\]. Perhaps more interesting is the concept of screening human disease genomes against pathogen datasets. In fact, it was this exact strategy that led to the discovery of Merkel cell polyomavirus in 2008 \[[@B18]\]. It may be that a subset of other cancers have a yet undiscovered viral etiology.

This study represents a pilot effort to gain experience with this exciting new technology, which was instructive as our group moves forward with large-scale projects. In addition to the small sample size, the quality of data generated limited by the ABI SOLiD platform with an average 30-fold coverage with 50 base pair paired-end reads yielded only 10-fold coverage over approximately two-thirds of the coding sequence. Thus, approximately a third of the exome was not adequately evaluated and important mutations could have been missed. We have recently completed characterizing a panel of head and neck cancer cell lines with 100-fold coverage with 100 base pair paired-end reads, and the results were vastly superior \[[@B19]\]. An average of 99% of the targeted exome had at least 10 reads and 90% had fiftyfold coverage. Perhaps more importantly, an expert bioinformatics team is critical to properly analyze the data. Although there are standard steps involved with aligning the sequencing data to the reference genome, false positive results can be frequent without adequate quality control measures. A carefully validated pipeline is necessary to filter spurious results in order to generate valid data.

It should be noted that tremendous insights can be gained by exome sequencing; however, whole genome sequencing offers the advantage to identify other genetic changes that can lead to tumorigenesis including copy number variation and translocations, in addition to point mutations, insertions, and deletions. Alterations in noncoding regions that may be important, such as promoters and miRNAs, would also be identified. The study by Stransky et al. reported whole genome sequencing in two patients and revealed markedly more translocations in the HPV-negative versus the HPV-positive tumors \[[@B7]\]. Ideally, future large-scale initiatives will be carried out using this more extensive but also more expensive technique to identify additional important genetic changes underlying HNSCC.

5. Conclusions {#sec5}
==============

Whole exome sequencing of head and neck cancers can provide important insights into the molecular biology of the disease. HPV-positive and negative head and neck cancers are molecularly distinct, and HPV-negative cancers tend to harbor more mutations. Multiple, integrated HPV 16 sequences were identified in the exome targets from the HPV positive patient. These matches were restricted to the HPV-positive patient\'s tumor profile providing evidence of the utility of screening exome sequences against pathogen databases.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplementary Tables S1 and S2.

The supplementary tables provide a complete listing of the mutations identified by our bioinformatics pipeline in the HPV-positive (Table S1) and HPV-negative (Table S2) tumor samples but not in the matched blood samples. This listing includes mutations found in both coding and non-coding regions.

###### 

Click here for additional data file.

###### 

Click here for additional data file.
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![Tumors from two patients were sectioned. Slices were stained with ((a) and (b)) H&E, ((c) and (d)) p16, or ((e) and (f)) HPV *in situ* hybridization. Panels represent magnified images of the complete section (inset).](ISRN.ONCOLOGY2012-809370.001){#fig1}

![PCR confirmation of the presence of HPV type 16 DNA in patient 1 and the absence of HPV type 16 sequences in patient 2.](ISRN.ONCOLOGY2012-809370.002){#fig2}

![Detection of HPV 16 sequences with the exome captures of the four patient samples. Short read sequences generated from the exome sequencing data denoted by the small bars were found exclusively in the DNA from the HPV-positive tumor but not in the matched blood from the same patient or the HPV-negative patient\'s tumor or blood with the exception of the nonspecific poly-A signal.](ISRN.ONCOLOGY2012-809370.003){#fig3}

###### 

Primers for HPV testing.

  Name       Sequence 5′ to 3′
  ---------- ---------------------------
  GAPDH F    GCTCATTTGCAGGGGGGAGCC
  GAPDH R    CTGATGATCTTGAGGCTGTTG
  HPV 16 F   TTGCAGATCATCAAGAACACGTAGA
  HPV 16 R   GTAGAGATCAGTTGTCTCTGGTTGC
  HPV 18 F   CAACCGAGCACGACAGGAACG
  HPV 18 R   TAGAAGGTCAACCGGAATTTTCAT

F: forward, R: reverse.

###### 

Patient demographics.

                     Patient 1             Patient 2
  ------------------ --------------------- -------------------------------
  Age                49                    81
  Gender             Male                  Female
  Primary site       Tonsil                Oral tongue
  Stage              T2N0                  T2N0
  Smoking            Nonsmoker             50 pack years
  Alcohol            Nondrinker            Rare
  Differentiation    Moderate              Moderate to poorly
  Adverse features   Perineural invasion   Perineural invasion
  p16                Positive              Negative
  HPV                Positive              Negative
  Treatment          TORS + ND             Transoral resection, ND, RFFF

HPV: human papillomavirus, TORS: transoral robotic surgery, ND: neck dissection, and RFFF: radial forearm free flap.

###### 

Coding mutations in the HPV-positive tumor.

  Chr   Position    Reference allele   Tumor allele   Zygosity   dbSNP ID      Region   Type            Gene      Transcript name   Exon   CDS position   Protein change   Stansky\*   Agrawal\*\*
  ----- ----------- ------------------ -------------- ---------- ------------- -------- --------------- --------- ----------------- ------ -------------- ---------------- ----------- -------------
  19    15789140    A                  G              Homo       rs609290      Exonic   Nonsynonymous   CYP4F12   NM_023944         3      c.A268G        p.I90V           Yes          
  10    88946876    G                  A              Hetero                   Exonic   Nonsynonymous   FAM35A    NM_019054         8      c.G2227A       p.D743N                       
  3     51930850    T                  C              Homo       rs57859638    Exonic   Nonsynonymous   IQCF1     NM_152397         3      c.A169G        p.K57E                        
  7     20180717    C                  G              Homo       rs3735615     Exonic   Nonsynonymous   MACC1     NM_182762         7      c.G2411C       p.R804T          Yes          
  14    64882380    A                  G              Hetero     rs1950902     Exonic   Nonsynonymous   MTHFD1    NM_005956         6      c.A401G        p.K134R                       
  7     100634194   C                  G              Hetero                   Exonic   Nonsynonymous   MUC12     NM_001164462      2      c.C350G        p.A117G                       
  19    9006667     A                  G              Homo       rs75101943    Exonic   Nonsynonymous   MUC16     NM_024690         44     c.T39581C      p.I13194T        Yes          
  19    9074122     T                  G              Homo                     Exonic   Nonsynonymous   MUC16     NM_024690         3      c.A13324C      p.T4442P         Yes          
  3     195517753   C                  T              Hetero                   Exonic   Nonsynonymous   MUC4      NM_018406         2      c.G698A        p.G233E          Yes          
  11    1017381     G                  C              Hetero     rs34912894    Exonic   Nonsynonymous   MUC6      NM_005961         61     c.C5420G       p.T1807S         Yes          
  19    50865535    A                  G              Homo       rs676314      Exonic   Nonsynonymous   NAPSA     NM_004851         2      c.T119C        p.I40T                        
  4     170345835   G                  C              Homo                     Exonic   Nonsynonymous   NEK1      NM_001199397      31     c.C3091G       p.Q1031E                      
  17    3195485     C                  T              Hetero                   Exonic   Nonsynonymous   OR3A1     NM_002550         1      c.G392A        p.R131Q                       
  3     98073075    A                  G              Hetero                   Exonic   Nonsynonymous   OR5K4     NM_001005517      1      c.A378G        p.I126M          Yes          
  5     140590766   A                  G              Homo       rs2910006     Exonic   Nonsynonymous   PCDHB12   NM_018932         1      c.A2287G       p.K763E                       
  12    27787878    G                  A              Hetero                   Exonic   Nonsynonymous   PPFIBP1   NM_001198916      4      c.G100A        p.D34N                        
  15    43827261    G                  C              Hetero                   Exonic   Nonsynonymous   PPIP5K1   NM_001190214      30     c.C3832G       p.H1278D                      
  1     12853378    T                  G              Hetero     rs112330886   Exonic   Nonsynonymous   PRAMEF1   NM_023013         2      c.T2G          p.M1R            Yes          
  X     135956575   G                  A              Hetero     rs78646793    Exonic   Nonsynonymous   RBMX      NM_002139         9      c.C902T        p.P301L                       
  6     33272855    G                  C              Homo       rs2071888     Exonic   Nonsynonymous   TAPBP     NM_172208         4      c.C779G        p.T260R                       
  12    11183046    C                  T              Hetero                   Exonic   Nonsynonymous   TAS2R31   NM_176885         1      c.G889A        p.V297M                       
  12    11213969    A                  G              Hetero     rs2599402     Exonic   Nonsynonymous   TAS2R46   NM_176887         1      c.T925C        p.S309P          Yes          
  3     100084425   T                  G              Homo                     Exonic   Nonsynonymous   TOMM70A   NM_014820         12     c.A1810C       p.K604Q          Yes          
  9     135277007   C                  T              Homo       rs3739916     Exonic   Nonsynonymous   TTF1      NM_007344         2      c.G1202A       p.R401Q                      Yes
  19    38378659    A                  T              Homo                     Exonic   Nonsynonymous   WDR87     NM_031951         6      c.T5535A       p.N1845K                      
  9     74975645    C                  G              Hetero                   Exonic   Nonsynonymous   ZFAND5    NM_001102421      2      c.G50C         p.G17A                        
  12    133732818   C                  T              Hetero                   Exonic   Nonsynonymous   ZNF10     NM_015394         5      c.C986T        p.S329F                       
  19    44933706    C                  T              Hetero     rs57014690    Exonic   Nonsynonymous   ZNF229    NM_014518         6      c.G1250A       p.S417N          Yes          
  19    57089050    C                  T              Hetero     rs4801177     Exonic   Nonsynonymous   ZNF470    NM_001001668      6      c.C1253T       p.T418I          Yes          
  19    52618497    A                  T              Hetero                   Exonic   Nonsynonymous   ZNF616    NM_178523         4      c.T1920A       p.N640K          Yes          
  2     71654175    G                  A              Homo       rs1804020     Exonic   Nonsynonymous   ZNF638    NM_001252612      24     c.G5176A       p.V1726M                      
  7     57528923    G                  C              Hetero                   Exonic   Nonsynonymous   ZNF716    NM_001159279      4      c.G756C        p.W252C                      

Chr: chromosome, \*mutations present in Stransky et al., Science 2011 \[[@B7]\], \*\*mutations present in Agrawal et al., Science 2011 \[[@B6]\], Homo: homozygous, Hetero: heterozygous.

###### 

Coding mutations in the HPV-negative tumor.

  Chr   Position    Reference allele   Tumor allele   Zygosity   dbSNP ID      Region     Type            Gene           Transcript name   Exon   CDS position   Protein change   Stansky\*   Agrawal\*\*
  ----- ----------- ------------------ -------------- ---------- ------------- ---------- --------------- -------------- ----------------- ------ -------------- ---------------- ----------- -------------
  2     73679256    C                  G              Homo                     Exonic     Nonsynonymous   ALMS1          NM_015120         8      c.C5599G       p.L1867V         Yes          
  10    37451586    G                  A              Hetero     rs12766884    Exonic     Nonsynonymous   ANKRD30A       NM_052997         16     c.G1742A       p.G581E          Yes          
  9     33385733    C                  T              Hetero                   Exonic     Nonsynonymous   AQP7           NM_001170         7      c.G657A        p.M219I                       
  17    42271663    G                  C              Homo                     Exonic     Nonsynonymous   ATXN7L3        NM_001098833      12     c.C1012G       p.P338A                       
  6     136599913   A                  T              Hetero                   Exonic     Nonsynonymous   BCLAF1         NM_001077441      4      c.T106A        p.S36T                        
  1     26646726    A                  G              Hetero     rs1071849     Exonic     Nonsynonymous   CD52           NM_001803         2      c.A119G        p.N40S                        
  1     26646730    A                  G              Homo       rs17645       Exonic     Nonsynonymous   CD52           NM_001803         2      c.A123G        p.I41M                        
  19    42213948    C                  G              Hetero                   Exonic     Nonsynonymous   CEACAM5        NM_004363         2      c.C414G        p.F138L                       
  12    31242362    A                  G              Hetero     rs3950588     Exonic     Nonsynonymous   DDX11          NM_030653         8      c.A818G        p.K273R          Yes          
  15    83657820    G                  C              Hetero                   Exonic     Stoploss        FAM103A1       NM_031452         3      c.G50C         p.X17S                        
  6     76023130    T                  G              Homo                     Exonic     Nonsynonymous   FILIP1         NM_015687         5      c.A2418C       p.Q806H,         Yes          
  1     152191709   C                  G              Hetero     rs6662450     Exonic     Nonsynonymous   HRNR           NM_001009931      3      c.G2396C       p.S799T          Yes          
  9     21202136    A                  G              Hetero     rs145794215   Exonic     Nonsynonymous   IFNA7          NM_021057         1      c.T29C         p.V10A                        
  7     100635103   A                  C              Hetero                   Exonic     Nonsynonymous   MUC12          NM_001164462      2      c.A1259C       p.E420A                       
  17    10404435    T                  G              Hetero                   Exonic     Nonsynonymous   MYH1           NM_005963         27     c.A3730C       p.K1244Q         Yes         Yes
  18    47364086    C                  T              Hetero                   Exonic     Nonsynonymous   MYO5B          NM_001080467      37     c.G4939A       p.D1647N         Yes          
  12    57106659    C                  G              Hetero                   Exonic     Nonsynonymous   NACA           NM_001113203      10     c.G2674C       p.E892Q          Yes          
  1     21795333    C                  G              Hetero                   Exonic     Nonsynonymous   NBPF3          NM_032264         3      c.C286G        p.Q96E           Yes         Yes
  10    115370274   T                  C              Homo       rs10749138    Exonic     Nonsynonymous   NRAP           NM_006175         30     c.A3442G       p.I1148V         Yes         Yes
  11    48346916    G                  C              Homo       rs77069283    Exonic     Nonsynonymous   OR4C3          NM_001004702      1      c.G424C        p.V142L          Yes          
  11    4608046     T                  A              Hetero                   Exonic     Nonsynonymous   OR52I2         NM_001005170      1      c.T4A          p.C2S                         
  11    56128081    A                  G              Hetero     rs10896290    Exonic     Nonsynonymous   OR8J1          NM_001005205      1      c.A359G        p.Y120C          Yes          
  11    56143823    G                  A              Homo       rs77614949    Exonic     Nonsynonymous   OR8U1, OR8U8   NM_001005204      1      c.G724A        p.G242S                       
  X     82764042    G                  C              Hetero     rs5921979     Exonic     Nonsynonymous   POU3F4         NM_000307         1      c.G710C        p.G237A          Yes          
  19    43709656    C                  G              Homo       rs11883278    Exonic     Nonsynonymous   PSG4           NM_213633         1      c.G33C         p.Q11H           Yes          
  14    21511497    C                  T              Homo       rs1243469     Exonic     Nonsynonymous   RNASE7         NM_032572         2      c.C346T        p.H116Y                       
  1     153004853   C                  T              Homo       rs3795382     Exonic     Nonsynonymous   SPRR1B         NM_003125         2      c.C32T         p.T11I                        
  6     33410273    T                  A              Homo                     Splicing   NA              SYNGAP1        NM_006772         14     c.2336+2T\>A                                 
  12    11174327    C                  T              Hetero     rs72475481    Exonic     Nonsynonymous   TAS2R19        NM_176888         1      c.G844A        p.G282R                       
  12    11183676    C                  T              Hetero     rs73049072    Exonic     Nonsynonymous   TAS2R31        NM_176885         1      c.G259A        p.V87I                        
  7     35244086    A                  T              Hetero                   Exonic     Nonsynonymous   TBX20          NM_001077653      7      c.T999A        p.N333K                       
  21    10910347    A                  G              Hetero     rs150482      Exonic     Nonsynonymous   TPTE           NM_199261         22     c.T1409C       p.L470P                       
  7     99669149    C                  T              Hetero                   Exonic     Nonsynonymous   ZNF3           NM_032924         6      c.G958A        p.A320T                       
  19    57839150    A                  G              Homo       rs8100491     Exonic     Nonsynonymous   ZNF543         NM_213598         4      c.A320G        p.Q107R          Yes          
  12    124497119   T                  A              Hetero                   Exonic     Nonsynonymous   ZNF664         NM_001204298      5      c.T428A        p.F143Y                       
  19    12501852    C                  T              Hetero                   Exonic     Nonsynonymous   ZNF799         NM_001080821      4      c.G1360A       p.G454R          Yes         

Chr: chromosome, \*mutations present in Stransky et al., Science 2011 \[[@B7]\], \*\*mutations present in Agrawal et al., Science 2011 \[[@B6]\], Homo: homozygous, Hetero: heterozygous.

[^1]: Academic Editors: R.-J. Bensadoun and H.-W. Lo
